[go: up one dir, main page]

ES2170770T3 - Utilizacion de isovaleramida como ansiolitico suave y agente sedante suave. - Google Patents

Utilizacion de isovaleramida como ansiolitico suave y agente sedante suave.

Info

Publication number
ES2170770T3
ES2170770T3 ES94920093T ES94920093T ES2170770T3 ES 2170770 T3 ES2170770 T3 ES 2170770T3 ES 94920093 T ES94920093 T ES 94920093T ES 94920093 T ES94920093 T ES 94920093T ES 2170770 T3 ES2170770 T3 ES 2170770T3
Authority
ES
Spain
Prior art keywords
soft
isovaleramide
sedante
ansiolytic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920093T
Other languages
English (en)
Inventor
Manuel F Balandrin
Wagenen Bradford C Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2170770T3 publication Critical patent/ES2170770T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE HA DESCUBIERTO QUE LA ISOVALERAMIDA PRESENTA UNA ACTIVIDAD ANSIOLITICA (REDUCTORA DE LA ANSIEDAD) SUAVE A NIVELES DE DOSIFICACION DE SUAVES A MODERADOS Y UNA ACTIVIDAD SEDATIVA SUAVE A NIVELES DE DOSIFICACION DE ALGUN MODO MAYORES. A DIFERENCIA DE OTROS MATERIALES QUE SE SUPONEN ANSIOLITICOS O LIGERAMENTE SEDATIVOS, LA ISOVALERAMIDA NO ES CITOTOXICA Y NO ESTIMULA PARADOJICAMENTE EL SISTEMA NERVIOSO CENTRAL. POR TANTO LA ISOVALERAMIDA ES UTIL COMO ANSIOLITICO SUAVE Y COMO AGENTE SEDATIVO SUAVE Y SE PUEDE OFRECER AL PUBLICO EN GENERAL.
ES94920093T 1993-06-11 1994-06-10 Utilizacion de isovaleramida como ansiolitico suave y agente sedante suave. Expired - Lifetime ES2170770T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/075,126 US5506268A (en) 1993-06-11 1993-06-11 Use of isovaleramide as a mild anxiolytic and sedative agent

Publications (1)

Publication Number Publication Date
ES2170770T3 true ES2170770T3 (es) 2002-08-16

Family

ID=22123718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920093T Expired - Lifetime ES2170770T3 (es) 1993-06-11 1994-06-10 Utilizacion de isovaleramida como ansiolitico suave y agente sedante suave.

Country Status (15)

Country Link
US (2) US5506268A (es)
EP (1) EP0706385B1 (es)
JP (2) JP3790267B2 (es)
KR (1) KR100341993B1 (es)
CN (1) CN1108793C (es)
AT (1) ATE213630T1 (es)
CA (1) CA2164842C (es)
DE (1) DE69429990T2 (es)
DK (1) DK0706385T3 (es)
ES (1) ES2170770T3 (es)
IL (1) IL109982A (es)
PT (1) PT706385E (es)
RU (1) RU2136271C1 (es)
TW (1) TW420606B (es)
WO (1) WO1994028888A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4113984C2 (de) * 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
US5786382A (en) * 1995-11-03 1998-07-28 Childers-Zadah; Vsande Use of valerian plant and/or root as a scent-attractant for stimulating canines and felines
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
CN1531924A (zh) * 1996-08-30 2004-09-29 NPSҩ�����޹�˾ 异戊酸衍生物类cns抑制剂在制备治疗头痛的药物中的用途
IL120006A (en) * 1997-01-14 2000-12-06 Yissum Res Dev Co Valnoctamide stereoisomers and a method for their synthesis and separation
AU763245B2 (en) 1997-12-10 2003-07-17 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
EP1059930B1 (en) * 1998-03-04 2005-05-11 Nps Pharmaceuticals, Inc. Compositions comprising isovaleramide and ibuprofen
EP1576962A1 (en) * 1998-03-04 2005-09-21 Nps Pharmaceuticals, Inc. Composition comprising isovaleramide and ibuprofen
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6346283B1 (en) * 1999-03-26 2002-02-12 Ancile Pharmaceuticals Use of valeriana for the treatment of restless leg syndrome and related disorders
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
RU2199309C1 (ru) * 2001-12-29 2003-02-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство нобрассит седативного и анксиолитического действия
RU2209062C1 (ru) * 2002-03-19 2003-07-27 Институт физиологии им. И.П.Павлова РАН Вещество, обладающее седативным действием
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
US20060025477A1 (en) * 2004-07-22 2006-02-02 Artman Linda D Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
KR102222910B1 (ko) 2019-04-30 2021-03-04 차은정 평상형 원목침대
KR102227555B1 (ko) 2019-12-24 2021-03-15 주식회사 리빙테크 황토볼이 구비된 편백나무 침대

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205083A (en) * 1968-03-30 1980-05-27 Kali-Chemie Aktiengesellschaft Cyclopentapyrans
FR2306687A2 (fr) * 1975-04-08 1976-11-05 Buzas Andre Derives d'acides phenoxy-acetiques, leur preparation et leur application en therapeutique
FR2209555B1 (es) * 1972-12-11 1975-11-28 Labaz
SU668261A1 (ru) * 1977-03-21 1985-03-15 Киевский научно-исследовательский институт фармакологии и токсикологии @ -Алкил- @ -( @ -оксифенил)-амиды 3,4,5-триметоксибензойной кислоты,обладающие нейролептической активностью
US4246282A (en) * 1979-06-07 1981-01-20 Labaz ω-Dialkylalkanoic acid derivatives used to induce antianoxic activity
DE3026579A1 (de) * 1980-07-14 1982-02-11 Kali-Chemie Pharma Gmbh, 3000 Hannover 2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
FR2648814B1 (fr) * 1989-06-26 1991-10-18 Lafon Labor L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique
DE4008403A1 (de) * 1990-03-16 1991-09-19 Merck Patent Gmbh Glykolsaeurederivate
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JP2006169259A (ja) 2006-06-29
IL109982A (en) 1998-09-24
WO1994028888A1 (en) 1994-12-22
ATE213630T1 (de) 2002-03-15
CN1127472A (zh) 1996-07-24
US5763494A (en) 1998-06-09
TW420606B (en) 2001-02-01
PT706385E (pt) 2002-07-31
IL109982A0 (en) 1994-10-07
AU7100694A (en) 1995-01-03
JP3790267B2 (ja) 2006-06-28
KR100341993B1 (ko) 2002-11-29
CA2164842A1 (en) 1994-12-22
JPH09501908A (ja) 1997-02-25
DK0706385T3 (da) 2002-04-29
AU701360B2 (en) 1999-01-28
DE69429990T2 (de) 2002-09-05
RU2136271C1 (ru) 1999-09-10
EP0706385B1 (en) 2002-02-27
CN1108793C (zh) 2003-05-21
CA2164842C (en) 2006-08-29
DE69429990D1 (de) 2002-04-04
EP0706385A1 (en) 1996-04-17
US5506268A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
ES2170770T3 (es) Utilizacion de isovaleramida como ansiolitico suave y agente sedante suave.
ES2141208T3 (es) Utilizacion de una cantidad eficaz de sustancias activas para el tratamiento de pieles mixtas.
PL321898A1 (en) Application of inorganic aerogles in pharmaceutics
ES2123064T3 (es) Uso de melatonina en pequeñas dosis orales como somnifero.
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
EA199900553A1 (ru) Чрескожная терапевтическая система
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
ZA902627B (en) Substituted 1,8-naphthyridines
HUT64691A (en) Cosmetic preparative with skin regenerative effect
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
GB2137089B (en) Pyrethroid-containing pharmaceutical compositions
AP2000001950A0 (en) Paroxetine maleate.
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
IL139303A0 (en) Treatment of arthritis and other similar conditions
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
UA28284A (uk) Природний лікувальний засіб (його варіанти)
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
MX9803681A (es) Inhibicion de la expresion de membrana.
ES2063455T3 (es) Nueva forma unitaria, solida y porosa que comprende particulas en forma de perlas asi como su preparacion.
UA10435A (uk) Спосіб стимуляції життєдіяльhості людиhи та пристрій для його здійсhеhhя
UA12462A (uk) Фалопротез і спосіб його імплаhтації

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 706385

Country of ref document: ES